Cargando…

Chronic Administration of Melatonin: Physiological and Clinical Considerations

Background: Exogenous melatonin is commonly used to treat insomnia, other sleep problems, and numerous medical illnesses, including Alzheimer’s disease, autism spectrum disorder, and mild cognitive impairment in adults and children. There is evolving information regarding issues with the use of chro...

Descripción completa

Detalles Bibliográficos
Autores principales: Givler, Donald, Givler, Amy, Luther, Patrick M., Wenger, Danielle M., Ahmadzadeh, Shahab, Shekoohi, Sahar, Edinoff, Amber N., Dorius, Bradley K., Jean Baptiste, Carlo, Cornett, Elyse M., Kaye, Adam M., Kaye, Alan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053496/
https://www.ncbi.nlm.nih.gov/pubmed/36976674
http://dx.doi.org/10.3390/neurolint15010031
_version_ 1785015427465740288
author Givler, Donald
Givler, Amy
Luther, Patrick M.
Wenger, Danielle M.
Ahmadzadeh, Shahab
Shekoohi, Sahar
Edinoff, Amber N.
Dorius, Bradley K.
Jean Baptiste, Carlo
Cornett, Elyse M.
Kaye, Adam M.
Kaye, Alan D.
author_facet Givler, Donald
Givler, Amy
Luther, Patrick M.
Wenger, Danielle M.
Ahmadzadeh, Shahab
Shekoohi, Sahar
Edinoff, Amber N.
Dorius, Bradley K.
Jean Baptiste, Carlo
Cornett, Elyse M.
Kaye, Adam M.
Kaye, Alan D.
author_sort Givler, Donald
collection PubMed
description Background: Exogenous melatonin is commonly used to treat insomnia, other sleep problems, and numerous medical illnesses, including Alzheimer’s disease, autism spectrum disorder, and mild cognitive impairment in adults and children. There is evolving information regarding issues with the use of chronic melatonin. Methods: The present investigation was a narrative review. Results: Melatonin usage has risen dramatically in recent years. Many countries only allow melatonin prescriptions. In the United States (U.S.), it is classified as a dietary supplement accessible over the counter and can be derived from animals, microorganisms, or, most commonly, made synthetically. No regulatory agency oversees its manufacturing or sale in the U.S. melatonin concentration of marketed preparations varies widely between product labels and manufacturers. Melatonin’s ability to induce sleep is detectable. However, it is modest for most people. Sleep length appears to be less important in sustained-release preparations. The optimal dosage is unknown, and routinely used amounts vary substantially. Melatonin’s short-term negative effects are minimal, resolve at medicine cessation, and do not usually prevent usage overall. Much research on long-term melatonin administration has found no difference between exogenous melatonin and placebo in terms of long-term negative effects. Conclusion: Melatonin at low to moderate dosages (approximately 5–6 mg daily or less) appears safe. Long-term usage appears to benefit certain patient populations, such as those with autism spectrum disorder. Studies investigating potential benefits in reducing cognitive decline and increased longevity are ongoing. However, it is widely agreed that the long-term effects of taking exogenous melatonin have been insufficiently studied and warrant additional investigation.
format Online
Article
Text
id pubmed-10053496
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100534962023-03-30 Chronic Administration of Melatonin: Physiological and Clinical Considerations Givler, Donald Givler, Amy Luther, Patrick M. Wenger, Danielle M. Ahmadzadeh, Shahab Shekoohi, Sahar Edinoff, Amber N. Dorius, Bradley K. Jean Baptiste, Carlo Cornett, Elyse M. Kaye, Adam M. Kaye, Alan D. Neurol Int Review Background: Exogenous melatonin is commonly used to treat insomnia, other sleep problems, and numerous medical illnesses, including Alzheimer’s disease, autism spectrum disorder, and mild cognitive impairment in adults and children. There is evolving information regarding issues with the use of chronic melatonin. Methods: The present investigation was a narrative review. Results: Melatonin usage has risen dramatically in recent years. Many countries only allow melatonin prescriptions. In the United States (U.S.), it is classified as a dietary supplement accessible over the counter and can be derived from animals, microorganisms, or, most commonly, made synthetically. No regulatory agency oversees its manufacturing or sale in the U.S. melatonin concentration of marketed preparations varies widely between product labels and manufacturers. Melatonin’s ability to induce sleep is detectable. However, it is modest for most people. Sleep length appears to be less important in sustained-release preparations. The optimal dosage is unknown, and routinely used amounts vary substantially. Melatonin’s short-term negative effects are minimal, resolve at medicine cessation, and do not usually prevent usage overall. Much research on long-term melatonin administration has found no difference between exogenous melatonin and placebo in terms of long-term negative effects. Conclusion: Melatonin at low to moderate dosages (approximately 5–6 mg daily or less) appears safe. Long-term usage appears to benefit certain patient populations, such as those with autism spectrum disorder. Studies investigating potential benefits in reducing cognitive decline and increased longevity are ongoing. However, it is widely agreed that the long-term effects of taking exogenous melatonin have been insufficiently studied and warrant additional investigation. MDPI 2023-03-15 /pmc/articles/PMC10053496/ /pubmed/36976674 http://dx.doi.org/10.3390/neurolint15010031 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Givler, Donald
Givler, Amy
Luther, Patrick M.
Wenger, Danielle M.
Ahmadzadeh, Shahab
Shekoohi, Sahar
Edinoff, Amber N.
Dorius, Bradley K.
Jean Baptiste, Carlo
Cornett, Elyse M.
Kaye, Adam M.
Kaye, Alan D.
Chronic Administration of Melatonin: Physiological and Clinical Considerations
title Chronic Administration of Melatonin: Physiological and Clinical Considerations
title_full Chronic Administration of Melatonin: Physiological and Clinical Considerations
title_fullStr Chronic Administration of Melatonin: Physiological and Clinical Considerations
title_full_unstemmed Chronic Administration of Melatonin: Physiological and Clinical Considerations
title_short Chronic Administration of Melatonin: Physiological and Clinical Considerations
title_sort chronic administration of melatonin: physiological and clinical considerations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053496/
https://www.ncbi.nlm.nih.gov/pubmed/36976674
http://dx.doi.org/10.3390/neurolint15010031
work_keys_str_mv AT givlerdonald chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT givleramy chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT lutherpatrickm chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT wengerdaniellem chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT ahmadzadehshahab chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT shekoohisahar chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT edinoffambern chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT doriusbradleyk chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT jeanbaptistecarlo chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT cornettelysem chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT kayeadamm chronicadministrationofmelatoninphysiologicalandclinicalconsiderations
AT kayealand chronicadministrationofmelatoninphysiologicalandclinicalconsiderations